Exercise-related signaling
Human exercise observations measured naturally occurring MOTS-C. Participants were not given a MOTS-C injection.
Read the publication
Physician-led care in the UAE
Peptide care · Pen
MOTS-C Pen
A mitochondrial peptide studied in exercise biology. Animal treatment findings and measurements of naturally occurring MOTS-C in people are different kinds of evidence.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
- Format
- Pen
- Strength
- 10 mg/ml
- Size
- 3 ml
- Route
- Subcutaneous injection
Suitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Where MOTS-C
has been studied.
Metabolic and aging interests come from mitochondrial biology and animal exercise findings. They do not establish an injectable benefit in people.
Physical function with age
Treated mice showed changes in performance measures. Human improvement from a pen or vial has not been established by this work.
Read the publicationSafety & suitability
Is MOTS-C right for you?
FDA reports insufficient human exposure information to assess MOTS-C safety and concerns about immunogenicity and peptide impurities.
Suitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
MOTS-C:
what has been studied.
The human research measured the body’s own MOTS-C after exercise; it did not test a MOTS-C injection. Treatment findings in mice do not establish the same benefit in people.
Treated mice showed changes in physical performance. In people, exercise was associated with changes in naturally occurring MOTS-C.
Mice; exercise observations in 10 men · Experimental mouse treatment; no human administration
What remains uncertain
Read the studyThe human observations do not demonstrate benefit or safety from administering MOTS-C.
About this evidence review
The human part of the highlighted study measured the body’s own MOTS-C after exercise. Participants were not treated with a MOTS-C pen or vial. Studies of analogs are separate.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss MOTS-C Pen. Your clinician decides which preparation, checks and follow-up are relevant.
01
The preparation
What exactly are we considering?
What is the exact ingredient, formulation and strength, and how would it be used?
02
Your assessment
What needs checking first?
Would blood glucose, HbA1c or a lipid profile help assess my metabolic health?
03
Your follow-up
How will we review the plan?
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is MOTS-C Pen considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
What should I know about the safety of MOTS-C Pen?
FDA reports insufficient human exposure information to assess MOTS-C safety and concerns about immunogenicity and peptide impurities.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
More in this area.
Explore other products discussed in these health topics, with the evidence for each.
DarDoc peptidesPen
Healthy aging · Sleep & focus
Epitalon Pen
10 mg/ml · 3 ml
Cell studies examine telomerase activity. An older clinical report explored a retinal condition, but human longevity benefits remain unestablished.
DarDoc peptidesPen
Metabolism
Tesamorelin Pen
10 mg/ml · 3 ml
Randomized trials show reductions in abdominal fat in adults with HIV-associated lipodystrophy, a specific medical condition.
DarDoc peptidesPen
Healthy aging
SS-31 Pen
80 mg/ml · 3 ml
Elamipretide, also known as SS-31, has a narrowly defined FDA-approved use in Barth syndrome. That is separate from general healthy aging.
Bring your questions
Make your next step
a conversation.
Want to understand where MOTS-C Pen fits? Discuss the evidence, your health history and the options with DarDoc.